Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)
N McCarthy, F Boyle, N Zdenkowski, J Bull, E Leong, A Simpson, G Kannourakis, PA Francis, J Chirgwin, E Abdi, V Gebski, AS Veillard, D Zannino, N Wilcken, L Reaby, DF Lindsay, HD Badger, JF Forbes
The Breast | CHURCHILL LIVINGSTONE | Published : 2014
Awarded by National Health and Medical Research Council of Australia
We thank the women who participated in the study, their doctors and the research teams at each of the participating hospitals; the Australia and New Zealand Breast Cancer Trials Group ANZ 0502 Study Team; the NeoGem steering committee, and the National Health and Medical Research Council of Australia (project grant ID 455513). Roche Products, Pty Limited (Australia) (drug, research grants), Eli Lilly Australia (drug, research grant), Sanofi-Aventis (drug), supported the trial and commented on findings of this study, but had no input into data analysis or interpretation.